story of the week
Osimertinib Improves Overall Survival in EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Osimertinib Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients With Leptomeningeal Metastases Regardless of T790M Mutational Status
J Thorac Oncol 2020 Jul 08;[EPub Ahead of Print], J Lee, Y La Choi, J Han, S Park, HA Jung, JM Sun, SH Lee, JS Ahn, K Park, MJ AhnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.